In 2023, the pharmaceutical products imports in China stood at an actual value of 42.32 billion US Dollars. The forecasted values for the upcoming years are as follows: 2024 with 44.09 billion USD, 2025 with 45.89 billion USD, 2026 with 47.66 billion USD, 2027 with 49.39 billion USD, and 2028 with 51.09 billion USD. Year-over-year variations demonstrate a consistent growth trend in the value of imports:
- 2024: 4.18%
- 2025: 4.08%
- 2026: 3.85%
- 2027: 3.63%
- 2028: 3.44%
The compound annual growth rate (CAGR) from 2024 to 2028 is approximately 3.84%, indicating a steady upward trend.
Future trends to watch for include increased demand for innovative therapies, changes in regulatory frameworks, and the impact of local pharmaceutical manufacturing capabilities designed to reduce dependence on imports.
